Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA149554)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM55632)
Article History
Received: 22 August 2020
Revised: 3 January 2021
Accepted: 18 January 2021
First Online: 18 February 2021
Compliance with ethical standards
:
: The authors declare they have no conflict of interest. PDL and JLS receive royalties from the sale of Cx43NT1 antibodies.